PMID- 34643895
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211111
IS  - 2193-8261 (Print)
IS  - 2193-6544 (Electronic)
IS  - 2193-6544 (Linking)
VI  - 10
IP  - 2
DP  - 2021 Dec
TI  - The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic 
      Patients: The EDGE Pilot Study.
PG  - 561-568
LID - 10.1007/s40119-021-00242-6 [doi]
AB  - INTRODUCTION: This prospective pharmacodynamic (PD) study assessed the effect of 
      the sodium-glucose co-transporter-2 inhibitor (SGLT2i), dapagliflozin, on 
      platelet reactivity. METHODS: Patients with stable coronary artery disease (CAD) 
      and type 2 diabetes mellitus (T2DM) (n = 27) who were on maintenance dual 
      antiplatelet therapy (DAPT) of aspirin 81 mg daily, and clopidogrel 75 mg daily 
      were recruited. Platelet function was evaluated with the VerifyNow P2Y(12) assay 
      (Werfen, Bedford, MA, USA) and assessed prior to initiation of and after 10 days 
      of treatment with dapagliflozin 10 mg once-daily dose regimen. Results were 
      compared with a paired t test. RESULTS: Treatment with dapagliflozin 
      significantly decreased P2Y12 reaction units (PRU) by 20%, (95% confidence 
      interval (CI) 8.5-32.6%, p value 0.002). The mean difference in PRU was 36.70 
      (95% CI 16.66-56.75). No patients experienced any serious adverse events (SAEs). 
      CONCLUSIONS: Significantly diminished platelet reactivity was observed on 
      dapagliflozin as compared to without dapagliflozin. This dedicated 
      pharmacodynamic study could be potentially informative and applicable for 
      Trinidadian stable CAD patients with T2DM on DAPT. Further studies are required 
      to confirm these exploratory findings. CLINICAL TRIAL REGISTRATION: EDGE 
      ClinicalTrials.gov number NCT04400760.
CI  - (c) 2021. The Author(s).
FAU - Seecheran, Naveen
AU  - Seecheran N
AUID- ORCID: 0000-0002-7779-0181
AD  - The University of the West Indies, Saint Augustine, Trinidad and Tobago. 
      naveen.seecheran@sta.uwi.edu.
FAU - Grimaldos, Kathryn
AU  - Grimaldos K
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Ali, Kabeer
AU  - Ali K
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Grimaldos, Gabriella
AU  - Grimaldos G
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Richard, Srivane
AU  - Richard S
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Ishmael, Aleena
AU  - Ishmael A
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Gomes, Ceylon
AU  - Gomes C
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Karan, Abhinav
AU  - Karan A
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Seecheran, Rajeev
AU  - Seecheran R
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Seecheran, Valmiki
AU  - Seecheran V
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Persad, Sangeeta
AU  - Persad S
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Abdullah, Harun
AU  - Abdullah H
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Peram, Lakshmipathi
AU  - Peram L
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Dookeeram, Darren
AU  - Dookeeram D
AD  - North Central Regional Health Authority, Mount Hope, Trinidad and Tobago.
FAU - Giddings, Stanley
AU  - Giddings S
AD  - The University of the West Indies, Saint Augustine, Trinidad and Tobago.
FAU - Motilal, Shastri
AU  - Motilal S
AD  - The University of the West Indies, Saint Augustine, Trinidad and Tobago.
FAU - Raza, Sadi
AU  - Raza S
AD  - HeartPlace Dallas, Dallas, TX, USA.
FAU - Tello-Montoliu, Antonio
AU  - Tello-Montoliu A
AD  - Universidad de Murcia, Murcia, Spain.
FAU - Schneider, David
AU  - Schneider D
AD  - Cardiovascular Research Institute of Vermont, Colchester, VT, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT04400760
PT  - Journal Article
DEP - 20211013
PL  - England
TA  - Cardiol Ther
JT  - Cardiology and therapy
JID - 101634495
PMC - PMC8555038
OTO - NOTNLM
OT  - Dapagliflozin
OT  - Platelet function
OT  - Platelet reactivity
OT  - Sodium-glucose co-transporter 2 inhibitor (SGLT2i)
OT  - VerifyNow
EDAT- 2021/10/14 06:00
MHDA- 2021/10/14 06:01
PMCR- 2021/10/13
CRDT- 2021/10/13 12:31
PHST- 2021/08/10 00:00 [received]
PHST- 2021/10/04 00:00 [accepted]
PHST- 2021/10/14 06:00 [pubmed]
PHST- 2021/10/14 06:01 [medline]
PHST- 2021/10/13 12:31 [entrez]
PHST- 2021/10/13 00:00 [pmc-release]
AID - 10.1007/s40119-021-00242-6 [pii]
AID - 242 [pii]
AID - 10.1007/s40119-021-00242-6 [doi]
PST - ppublish
SO  - Cardiol Ther. 2021 Dec;10(2):561-568. doi: 10.1007/s40119-021-00242-6. Epub 2021 
      Oct 13.